Stocks To Watch on September 21: GIFT Nifty on the NSE IX traded 48 points, or 0.24 per cent, lower at 19,857.50, signaling that Dalal Street was headed for negative start on Thursday. Here’s a slew of stocks that will be in focus today for various reasons.
Infosys: The IT major has tied up with NVIDIA to develop generative AI applications and solutions.
EMS: Water and sewage infra company EMS will list on Thursday. The issue price is Rs 211 and the stock is commanding a premium of 39 per cent in the grey market, as per ipowatch.com.
SJVN: The government will sell 96.667 million shares, or 2.46 per cent stake, in the company with an option to sell additional 2.46 per cent stake under offer for sale (OFS) route. At the floor price of Rs 69 a share, the sale of the entire 4.92 per cent stake will fetch over Rs 650 crore. The offer will open for non-retail investors today, and retail investors on Friday (Sept 22).
Cipla: An inspection by the USFDA, at the manufacturing facility of InvaGen Pharmaceuticals Inc., New York, USA, a wholly-owned subsidiary of the company, has concluded with five observations in Form 483. There are no repeat or data integrity (DI) observations. The company will address these comprehensively within stipulated time, Cipla said in a statement.
State Bank of India, KFin Technologies: SBI has appointed KFin Technologies as the Registrar and Share Transfer Agent (RTA) in place of existing RTA Alankit Assignments.
Sheela Foam: The QIP Committee has decided to open the QIP on September 20 at a floor price of Rs 1,133.99 per equity share. It will meet on September 25 to consider and approve the issue price of QIP.
DCB Bank: The Reserve Bank of India has accorded its approval to HDFC Asset Management Company to acquire aggregate holding of up to 9.5 per cent of the Bank. The AMC has been advised by the RBI to acquire the shareholding within a period of one year from the date of approval.
Apollo Tyres: The company has stopped bias and OTR tyre production at their manufacturing facility in Limda, Gujarat.
Zydus Lifesciences: Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1%, which is used to treat acne. Clindamycin Phosphate Gel USP, 1% had annual sales of $37 million in the United States (IQVIA MAT July 2023).
Shree Renuka Sugars: The Board will meet on September 23 to consider and approve entering into a binding agreement for investment in 100 per cent equity shares in a sugar manufacturing company located in Uttar Pradesh, India.
Comments
0 comment